Methods and compositions for detecting cancer using components of the U2 spliceosomal particle
OwnerJay Stoerkerinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to cancer-associated proteins and nucleic acids that encode or bind specifically to cancer-associated proteins, which represent markers for cancer detection. Specifically, the invention provides a family of methods and compositions for detecting cancer, for example, breast cancer, in an individual using components of the U2 spliceosomal particle. A target cancer-associated protein may be detected, for example, by reacting the sample with a labeled binding moiety, for example, a labeled antibody capable of binding specifically to the protein. The invention also provides kits useful in the detection of cancer in an individual.
Claims39
A method of diagnosing cancer in a mammal, the method comprising the steps of:
- (a) disrupting a complex in a tissue or body fluid sample from a mammal, the complex comprising one or more components of spliceosomal particle U2;
- and
- (b) detecting a component of spliceosomal particle U2, wherein the presence of the component is indicative of the presence of cancer in the mammal.
A method of diagnosing cancer in a mammal, the method comprising the steps of:
- (a) disrupting a complex in a tissue or body fluid sample from a mammal, the complex comprising one or more components of spliceosomal particle U2;
- and
- (b) measuring the amount of the component of spliceosomal particle U2, wherein the amount of the component is indicative of the presence of cancer in the mammal.
A method of diagnosing cancer in a mammal, the method comprising the step of detecting in a tissue or body fluid sample isolated from the mammal the presence of a component of spliceosomal particle U2, which if present is indicative of cancer in the mammal, provided that the component is not U2 snRNP B″.
A method of diagnosing cancer in a mammal, the method comprising the step of measuring in a tissue or body fluid sample isolated from the mammal an amount of a component of spliceosomal particle U2, wherein the amount is indicative of cancer in the mammal, provided that the component is not U2 snRNP B″.
A method of diagnosing cancer in a mammal, the method comprising the steps of:
- (a) combining a tissue or body fluid sample isolated from the mammal with a purified binding moiety capable of binding specifically to a component of spliceosomal particle U2 thereby to form a complex comprising the binding moiety and the component, provided that the component is not U2 snRNP B″;
- and
- (b) detecting the presence of the complex, which, if present, is indicative of the presence of cancer in the mammal.
A method of diagnosing cancer in a mammal, the method comprising the steps of:
- (a) combining a tissue or body fluid sample isolated from the mammal with a purified binding moiety capable of binding specifically to a component of spliceosomal particle U2 thereby to form a complex comprising the binding moiety and the component, provided that the component is not U2 snRNP B″;
- and
- (b) measuring the amount of the complex, wherein an amount of the complex greater than or equal to a threshold value is indicative of the presence of cancer in the mammal.
A method of detecting one or more snRNAs comprising 2,2,7-trimethylguanosine in a body fluid sample isolated from a mammal, the method comprising:
- (a) contacting the sample with a binding moiety that specifically binds 2,2,7-trimethylguanosine, such that, if an snRNA comprising 2,2,7-trimethylguanosine is present in the sample, the snRNA binds to the moiety to produce a complex;
- and
- (b) detecting the presence, absence or amount of the complex.
A kit comprising:
- (a) a purified binding moiety that specifically binds 2,2,7-trimethylguanosine;
- and
- (b) one or more molecules complementary to at least a portion of a U2 snRNA.
A kit for detecting cancer, the kit comprising:
- (a) a purified binding moiety that specifically binds U2 snRNA;
- and
- (b) a reference sample having an amount of U2 snRNA indicative of the presence of cancer.
Dependencies are inferred from the claim text.